Aptevo Therapeutics Inc. (NASDAQ:APVO) Sees Large Decrease in Short Interest

Aptevo Therapeutics Inc. (NASDAQ:APVO) saw a large drop in short interest in August. As of August 31st, there was short interest totalling 61,400 shares, a drop of 80.2% from the August 15th total of 310,700 shares. Based on an average daily trading volume, of 5,720,000 shares, the short-interest ratio is currently 0.0 days.

Analyst Upgrades and Downgrades

Separately, StockNews.com assumed coverage on shares of Aptevo Therapeutics in a research note on Wednesday. They set a “sell” rating for the company.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Aptevo Therapeutics stock. Armistice Capital LLC purchased a new position in Aptevo Therapeutics Inc. (NASDAQ:APVO) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 749,234 shares of the biotechnology company’s stock, valued at approximately $229,000. Armistice Capital LLC owned approximately 18.36% of Aptevo Therapeutics as of its most recent filing with the Securities and Exchange Commission. 8.06% of the stock is currently owned by hedge funds and other institutional investors.

Aptevo Therapeutics Trading Down 2.4 %

Aptevo Therapeutics stock opened at $0.35 on Friday. Aptevo Therapeutics has a one year low of $0.28 and a one year high of $21.56. The stock has a fifty day moving average of $0.38 and a 200 day moving average of $1.57.

Aptevo Therapeutics (NASDAQ:APVO) last issued its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($1.67) earnings per share for the quarter, topping the consensus estimate of ($1.93) by $0.26. As a group, sell-side analysts forecast that Aptevo Therapeutics will post -4.3 earnings per share for the current fiscal year.

About Aptevo Therapeutics

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.